Selective effects of DNA damaging agents on HIV long terminal repeat activation and virus replication in vitro.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Selective effects of DNA damaging agents on HIV long terminal repeat activation and virus replication in vitro.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):109-16. Unique Identifier : AIDSLINE MED/96147310
Manome Y; Yao XJ; Kufe DW; Cohen EA; Fine HA; Division of Cancer Pharmacology, Dana Farber Cancer Institute,; Harvard Medical School, Boston, Massachusetts 02115, USA.

Abstract: Much attention has recently focused on the observation that UV light can activate the long terminal repeat (LTR) of the human immunodeficiency virus (HIV). Although the mechanism of LTR activation remains obscure, several lines of investigation have suggested that it is a result of activation of the NF-kappa B transcription factor(s) following signaling events related to generalized DNA damage. In this report, we present data demonstrating that HIV LTR activation is not a general consequence of cellular DNA damage, but rather a process unique to specific genotoxic stimuli, and that it does not necessarily depend on activation of NF-kappa B. Furthermore, we demonstrate that several of these agents can significantly increase HIV replication and accelerate CD4-positive lymphocyte cytotoxicity in vitro. These findings, therefore, could have clinical significance to AIDS patients with malignancies who are undergoing radiotherapy and chemotherapy.

Keywords: Antineoplastic Agents/*PHARMACOLOGY Comparative Study CD4-Positive T-Lymphocytes/DRUG EFFECTS/RADIATION EFFECTS/ VIROLOGY *DNA Damage/DRUG EFFECTS/RADIATION EFFECTS DNA, Viral/*DRUG EFFECTS/RADIATION EFFECTS Gene Expression Regulation, Viral/DRUG EFFECTS/RADIATION EFFECTS Hela Cells/DRUG EFFECTS/RADIATION EFFECTS/VIROLOGY Human HIV Long Terminal Repeat/*DRUG EFFECTS/RADIATION EFFECTS HIV-1/*PHYSIOLOGY NF-kappa B/BIOSYNTHESIS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Ultraviolet Rays *Virus Activation/DRUG EFFECTS/RADIATION EFFECTS *Virus Replication/DRUG EFFECTS/RADIATION EFFECTS JOURNAL ARTICLE
960530
M9651039

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .